Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience

HIV Clinical Trials

Volumn 9, Issue 1, 2008, Pages 11-25

  Demeter, Lisa M ^a,j   DeGruttola, Victor ^b   Lustgarten, Stephanie ^b   Bettendorf, Daniel ^b   Fischl, Margaret ^c   Eshleman, Susan ^d   Spreen, William ^e   Nguyen, Bach Yen ^f   Koval, Christine E ^a   Eron Jr , Joseph J ^g   Hammer, Scott ^h   Squires, Kathleen ⁱ  

^a UNIVERSITY OF ROCHESTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GLAXOSMITHKLINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j Box 689 ^*  (United States)

more..

Author keywords

Efavirenz hypersusceptibility; HIV drug resistance; NNRTI resistance; Nucleoside resistance

Indexed keywords

ABACAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 38949183670     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0901-11     Document Type: Article

References (37)

1. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New Engl J Med. 1999;341(25):1865-1873.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725-733.
3. Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003;188(5):625-634.
4. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-1861.
5. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293-2303.
6. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046.
7. Hammer SM, Bassett R, Squires KE, et al. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8(6):507-518.
8. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288(2):169-180.
9. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182(5):1375-1384.
10. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348(22):2186-2195.
11. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-2185.
12. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000;5(1):41-48.
13. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14(9):F83-93.
14. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353(9171):2195-2199.
15. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37(1): 113-128.
16. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2007; 1-136. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 5, 2007
17. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1 : clinical, phenotypic and genotypic correlates. AIDS. 2002;16(15):F41-47.
18. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J Virol. 2002;76(17):8659-8666.
19. Leigh Brown AJ, Frost SD, Good B, et al. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol. 2004;78(5):2242-2246.
20. Haubrich RH, Jiang H, Swanstrom R, et al. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin Trials. 2007;8(2):63-67.
21. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002; 16(15):F33-40.
22. Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS. 2001;15(9):1125-1132.
23. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17(6):821-830.
24. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of phenotypic hypersusceptibility to efavirenz among 446 baseline isolates from five ACTG studies. Antiviral Ther. 2003:Abstract 43.
25. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18(13):1781-1785.
26. Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 1181, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS. 2006;20(7):981-984.
27. Tozzi V, Zaccarelli M, Narciso P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis. 2004;189(9):1688-1695.
28. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42(2):269-276.
29. Cunningham S, Ank B, Lewis D, et al. Performance of the Applied Biosystems Viroseq Human Immunodeficiency Virus Type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001;39(4):1254-1257.
30. Mracna M, Becker-Pergola G, Dileanis J, et al. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol. 2001;39(12):4323-4327.
31. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11(3):92-96.
32. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44(9):2475-2484.
33. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75(11):4999-5008.
34. Kleim JP, Rosner M, Winkler I, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 - >Val or Ile and Val-75 - >Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA. 1996;93(1):34-38.
35. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol. 2003;77(2):1512-1523.
36. Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during therapy and evidence of compensation for the reduced fitness of K103N+L100I by the nucleoside resistance mutation L74V. Virology. 2006;353:184-192.
37. Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M. HIV-1 reverse transciptase and protease reistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther. 2003;8:111-120.